A Prospective Study of AFree Oral Spray as an Adjuvant Therapy for Mild and Moderate COVID-19 in Community Health Stations: Clinical Progression and Viral Clearance Outcomes

Abstract: in vivo 37: 2155-2160 (2023) doi:10.21873/invivo.13313 A Prospective Study of AFree Oral Spray as an Adjuvant Therapy for Mild and Moderate COVID-19 in Community Health Stations: Clinical Progression and Viral Clearance Outcomes DUONG T. TRAN1,2, TRUONG N. PHAM1,3, NHUNG HT NGUYEN4, HAU D. TRAN5, HUY Q. HOANG6, BO HAN7 and BA X. HOANG7 119-8 Hospital, Ministry of Public Security, Hanoi, Vietnam; 2Faculty of Medicine, Dai Nam University, Hanoi, Vietnam; 3Department of Experimental Surgery and Preclinical Study - University of Medicine and Pharmacy, Hanoi National University, Hanoi, Vietnam; 4University of Medical Technology, Department of Clinical Laboratory, Hai Duong, Vietnam; 5National Children Hospital, Department of Oncology, Hanoi, Vietnam; 6Natural Health Medical Center, Lawndale, CA, U.S.A.; 7Nimni-Cordoba Tissue Engineering and Drug Discovery Lab, Department of Surgery, Keck School of Medicine of University of Southern California, Los Angeles, CA, U.S.A. Abstract. Background/Aim: The aim of this study was to evaluate the safety and efficacy of AFree oral spray, in combination with Standard of Care, in treating mild to moderate COVID-19 patients. This was an open-label, single-blinded, and controlled randomized clinical trial. Patients and Methods: The study involved 1,252 patients, who were randomly assigned to either the control or study group, with 626 patients in each group. Patients in the control group were treated with Standard of Care recommended by the Ministry of Health of Vietnam, while patients in the study group received AFree oral spray in addition to Standard of Care for a period of 10 days. The clinical progression and outcomes of both groups were compared. Results: The results showed that the proportion of patients with clinical symptoms on the 5th, 7th and 10th Correspondence to: Ba X. Hoang, MD, Ph.D., Nimni-Cordoba Tissue Engineering and Drug Discovery Lab, Department of Surgery, Keck School of Medicine, University of Southern California, BMT-302, 1333 San Pablo Street, Los Angeles, CA, U.S.A. Tel: +1 3234422242, e-mail: baxuanho@usc.edu Key Words: COVID-19, Zinc, Iodide, dimethyl sulfoxide, DMSO, AFree, viral infection, SARS-COV-2. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY-NC-ND) 4.0 international license (https://creativecommons.org/licenses/by-nc-nd/4.0). days were significantly lower in the study group (45.05%, 3.19% and 0%, respectively) compared to the control group (86.10%, 67.73% and 22.84%, respectively). Additionally, the rate of Real-time PCR test positivity for COVID-19 was significantly lower in the study group compared to the control group on the 4th, 7th, and 10th days (82.75% vs. 98.72%, 9.27% vs. 92.97%, and 1.12% vs. 50.48%, respectively). Furthermore, no side effects or complications related to AFree oral spray were recorded in the study group. Conclusion: The use of AFree oral spray resulted in significant improvements in clinical symptoms, recovery time, and viral clearance in COVID-19 patients with mild to moderate symptoms. This therapy has been shown to be safe and can be used as an adjuvant treatment for COVID-19 as well as other respiratory viral infections. COVID-19 is a highly contagious disease that can cause a wide range of clinical symptoms, ranging from mild to severe. In the worst cases, it can lead to the development of respiratory distress syndrome, sepsis, septic shock, and..